Dermata Therapeutics Inc (DRMA)

$0.96 +0.03 (2.98%)
Market Cap 5.38M
Revenue (ttm) 0.00
Net Income (ttm) -12.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 148,766
Avg Vol 1,891,240
Day's Range N/A - N/A
Shares Out 5.43M
Stochastic %K 2%
Beta 0.58
Analysts Strong Sell
Price Target $6.00

Latest News on DRMA

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 8:15 PM EDT - 7 days ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 10:21 AM EDT - 8 days ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 9:57 AM EDT - 8 days ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025, 8:00 AM EDT - 8 days ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 4:16 PM EDT - 17 days ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Mar 4, 2025, 8:03 AM EST - 4 weeks ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025, 7:58 AM EST - 5 weeks ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Jan 29, 2025, 4:05 PM EST - 2 months ago

Dermata to Present on BioPub on January 31, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 28, 2025, 4:05 PM EST - 2 months ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 23, 2025, 4:15 PM EST - 2 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 2 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Jan 21, 2025, 8:00 AM EST - 2 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 16, 2024, 9:00 AM EST - 3 months ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024, 9:00 AM EST - 4 months ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 3, 2024, 9:00 AM EST - 4 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:15 PM EST - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Nov 11, 2024, 8:35 AM EST - 5 months ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Oct 8, 2024, 4:15 PM EDT - 6 months ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 17, 2024, 5:15 PM EDT - 7 months ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 7 months ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Sep 5, 2024, 4:05 PM EDT - 7 months ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:05 PM EDT - 8 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 17, 2024, 9:00 AM EDT - 9 months ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 17, 2024, 8:30 AM EDT - 11 months ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 11 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Feb 1, 2024, 9:00 AM EST - 1 year ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Jan 4, 2024, 4:05 PM EST - 1 year ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 20, 2023, 4:05 PM EST - 1 year ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 1:30 PM EST - 1 year ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 16, 2023, 8:00 AM EST - 1 year ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 1 year ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:15 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 27, 2023, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 13, 2023, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Jun 8, 2023, 9:00 AM EDT - 1 year ago

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 26, 2023, 4:00 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 24, 2023, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

Apr 20, 2023, 6:00 AM EDT - 2 years ago

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

Mar 16, 2023, 1:15 PM EDT - 2 years ago

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Feb 21, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

Dec 5, 2022, 8:30 AM EST - 2 years ago

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Nov 10, 2022, 5:20 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

Aug 24, 2022, 4:05 PM EDT - 2 years ago

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase